ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Nanofluid-Enhanced Laser Lithotripsy Using Conducting Polymer Nanoparticles.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Visibly Transparent, Near-Infrared Absorbing Nanofluids Enable High-Efficiency and Safe Laser Lithotripsy.bioRxiv : the preprint server for biology · 2026Article
- Nanofluid-Enhanced Laser Lithotripsy Using Conducting Polymer Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Urinary stone disease, characterized by the hard mineral deposits in the urinary tract, has seen a rising prevalence globally. This condition often leads to severe pain and requires medical intervention. Laser lithotripsy, a minimally invasive treatment, uses laser to fragment urinary stones to facilitate removal or natural passage. Among available laser technologies, Ho:YAG laser has established itself as the gold standard for three decades. Efforts to improve ablation efficiency have focused on laser parameters such as pulse energy and frequency. This study introduces an ablation enhancement strategy that incorporates nanoparticles with strong near-infrared absorption into the surrounding fluid to enhance light-matter interaction. Using 0.03 wt.% PEDOT:PSS nanofluid improves stone ablation efficiency by 38-727% in spot treatment and 26-75% in scanning treatment with a clinical Ho:YAG laser lithotripter. The highly absorbing nanofluid accelerates vapor tunnel formation, boosts laser energy transmission, and permeates stone pores to enhance damage, without increasing thermal tissue injury. Cytotoxicity tests also confirmed minimal toxicity at appropriate concentrations. This nanofluid-based approach offers a promising advancement for more efficient and safer laser lithotripsy. Further work should address the remaining challenges for clinical translation, including aggregation in saline, efficacy in real human kidney stones, and comprehensive animal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.